WO1998041519A1
(en)
*
|
1997-03-18 |
1998-09-24 |
Smithkline Beecham Corporation |
Novel cannabinoid receptor agonists
|
AU766988B2
(en)
|
1998-04-21 |
2003-10-30 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Cannabinoids as antioxidants and neuroprotectants
|
DE69910373T2
(de)
*
|
1998-05-04 |
2004-04-01 |
The University Of Connecticut, Farmington |
Analgetische und immunomodulierende cannabinoiden
|
US7589220B2
(en)
*
|
1998-06-09 |
2009-09-15 |
University Of Connecticut |
Inhibitors of the anandamide transporter
|
US7897598B2
(en)
*
|
1998-06-09 |
2011-03-01 |
Alexandros Makriyannis |
Inhibitors of the anandamide transporter
|
US7161016B1
(en)
|
1998-11-24 |
2007-01-09 |
University Of Connecticut |
Cannabimimetic lipid amides as useful medications
|
US7276613B1
(en)
|
1998-11-24 |
2007-10-02 |
University Of Connecticut |
Retro-anandamides, high affinity and stability cannabinoid receptor ligands
|
FR2789079B3
(fr)
*
|
1999-02-01 |
2001-03-02 |
Sanofi Synthelabo |
Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
|
US8084467B2
(en)
*
|
1999-10-18 |
2011-12-27 |
University Of Connecticut |
Pyrazole derivatives as cannabinoid receptor antagonists
|
US6943266B1
(en)
*
|
1999-10-18 |
2005-09-13 |
University Of Connecticut |
Bicyclic cannabinoid agonists for the cannabinoid receptor
|
US7119108B1
(en)
*
|
1999-10-18 |
2006-10-10 |
University Of Connecticut |
Pyrazole derivatives as cannabinoid receptor antagonists
|
MXPA02005103A
(es)
|
1999-10-18 |
2003-09-25 |
Alexipharma Inc |
Ligandos selectivos del receptor de canabinoide (cb2) perifericos.
|
US6900236B1
(en)
*
|
1999-10-18 |
2005-05-31 |
University Of Connecticut |
Cannabimimetic indole derivatives
|
US7393842B2
(en)
*
|
2001-08-31 |
2008-07-01 |
University Of Connecticut |
Pyrazole analogs acting on cannabinoid receptors
|
US7741365B2
(en)
*
|
1999-10-18 |
2010-06-22 |
University Of Connecticut |
Peripheral cannabinoid receptor (CB2) selective ligands
|
FR2800375B1
(fr)
*
|
1999-11-03 |
2004-07-23 |
Sanofi Synthelabo |
Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant
|
US6974568B2
(en)
*
|
2000-05-23 |
2005-12-13 |
The Regents Of The University Of California |
Treatment for cough
|
US20020091114A1
(en)
|
2000-10-04 |
2002-07-11 |
Odile Piot-Grosjean |
Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
|
US8449908B2
(en)
*
|
2000-12-22 |
2013-05-28 |
Alltranz, Llc |
Transdermal delivery of cannabidiol
|
WO2002058636A2
(en)
*
|
2001-01-26 |
2002-08-01 |
University Of Connecticut |
Novel cannabimimetic ligands
|
CA2436133A1
(en)
|
2001-01-29 |
2002-08-08 |
University Of Connecticut |
Receptor selective cannabimimetic aminoalkylindoles
|
JP4312594B2
(ja)
*
|
2001-07-13 |
2009-08-12 |
ユニバーシティ オブ コネチカット |
新規な二環式及び三環式カンナビノイド
|
WO2003007887A2
(en)
|
2001-07-20 |
2003-01-30 |
Merck & Co., Inc. |
Substituted imidazoles as cannabinoid receptor modulators
|
CN1589269A
(zh)
*
|
2001-10-26 |
2005-03-02 |
康涅狄格大学 |
杂1,2-二氢化茚:一类新型有效的大麻配体
|
WO2003063781A2
(en)
*
|
2002-01-29 |
2003-08-07 |
Merck & Co., Inc. |
Substituted imidazoles as cannabinoid receptor modulators
|
US7351729B2
(en)
|
2002-03-08 |
2008-04-01 |
Signal Pharmaceuticals, Llc |
JNK inhibitors for use in combination therapy for treating or managing proliferative disorders and cancers
|
DE60334787D1
(de)
*
|
2002-03-12 |
2010-12-16 |
Merck Sharp & Dohme |
Substituierte amide
|
CA2479618A1
(en)
*
|
2002-03-26 |
2003-10-09 |
William K. Hagmann |
Spirocyclic amides as cannabinoid receptor modulators
|
US7271266B2
(en)
*
|
2002-03-28 |
2007-09-18 |
Merck & Co., Inc. |
Substituted 2,3-diphenyl pyridines
|
WO2003087037A1
(en)
*
|
2002-04-05 |
2003-10-23 |
Merck & Co., Inc. |
Substituted aryl amides
|
US7667053B2
(en)
*
|
2002-04-12 |
2010-02-23 |
Merck & Co., Inc. |
Bicyclic amides
|
US6825209B2
(en)
|
2002-04-15 |
2004-11-30 |
Research Triangle Institute |
Compounds having unique CB1 receptor binding selectivity and methods for their production and use
|
US7105526B2
(en)
|
2002-06-28 |
2006-09-12 |
Banyu Pharmaceuticals Co., Ltd. |
Benzimidazole derivatives
|
ES2301833T3
(es)
|
2002-07-29 |
2008-07-01 |
Hoffmann La Roche |
Derivados de benzodioxol.
|
AU2003257145B2
(en)
*
|
2002-08-02 |
2008-11-13 |
Merck Sharp & Dohme Corp. |
Substituted furo (2,3-b) pyridine derivatives
|
CA2496097A1
(en)
|
2002-08-23 |
2004-03-04 |
University Of Connecticut |
Keto cannabinoids with therapeutic indications
|
AR041268A1
(es)
*
|
2002-09-19 |
2005-05-11 |
Solvay Pharm Bv |
Derivados de la 1h -1,2,4- triazol-3-carboxamida que tienen actividad agonista, agonista parcial, agonista inversa o antagonista del receptor cb 1 de cannabinoide y composiciones farmaceuticas que los contienen
|
US7765162B2
(en)
*
|
2002-10-07 |
2010-07-27 |
Mastercard International Incorporated |
Method and system for conducting off-line and on-line pre-authorized payment transactions
|
SE0203070D0
(en)
*
|
2002-10-16 |
2002-10-16 |
Astrazeneca Ab |
Novel compounds
|
WO2004035566A1
(en)
*
|
2002-10-18 |
2004-04-29 |
Pfizer Products Inc. |
Cannabinoid receptor ligands and uses thereof
|
ITMI20022228A1
(it)
*
|
2002-10-21 |
2004-04-22 |
Dinamite Dipharma S P A |
Sali di clopidogrel con acidi alchil-solforici.
|
US7129239B2
(en)
*
|
2002-10-28 |
2006-10-31 |
Pfizer Inc. |
Purine compounds and uses thereof
|
US7247628B2
(en)
*
|
2002-12-12 |
2007-07-24 |
Pfizer, Inc. |
Cannabinoid receptor ligands and uses thereof
|
CN100360527C
(zh)
|
2003-01-02 |
2008-01-09 |
霍夫曼-拉罗奇有限公司 |
Cb1受体反激动剂
|
MXPA05007114A
(es)
*
|
2003-01-02 |
2005-08-26 |
Hoffmann La Roche |
Nuevos agonistas inversos del receptor cb1.
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
US7329658B2
(en)
*
|
2003-02-06 |
2008-02-12 |
Pfizer Inc |
Cannabinoid receptor ligands and uses thereof
|
US7176210B2
(en)
*
|
2003-02-10 |
2007-02-13 |
Pfizer Inc. |
Cannabinoid receptor ligands and uses thereof
|
US20040214856A1
(en)
*
|
2003-04-23 |
2004-10-28 |
Pfizer Inc |
Cannabinoid receptor ligands and uses thereof
|
US7145012B2
(en)
|
2003-04-23 |
2006-12-05 |
Pfizer Inc. |
Cannabinoid receptor ligands and uses thereof
|
US7268133B2
(en)
*
|
2003-04-23 |
2007-09-11 |
Pfizer, Inc. Patent Department |
Cannabinoid receptor ligands and uses thereof
|
US7141669B2
(en)
*
|
2003-04-23 |
2006-11-28 |
Pfizer Inc. |
Cannabiniod receptor ligands and uses thereof
|
US7232823B2
(en)
|
2003-06-09 |
2007-06-19 |
Pfizer, Inc. |
Cannabinoid receptor ligands and uses thereof
|
US20040259887A1
(en)
*
|
2003-06-18 |
2004-12-23 |
Pfizer Inc |
Cannabinoid receptor ligands and uses thereof
|
KR100809201B1
(ko)
|
2003-06-20 |
2008-02-29 |
에프. 호프만-라 로슈 아게 |
카나바노이드 수용체 1 역작용제로서 2-아미노벤조티아졸
|
FR2856683A1
(fr)
*
|
2003-06-25 |
2004-12-31 |
Sanofi Synthelabo |
Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application en therapeutique
|
FR2856684B1
(fr)
|
2003-06-26 |
2008-04-11 |
Sanofi Synthelabo |
Derives de diphenylpyridine, leur preparation et leur application en therapeutique
|
WO2005009479A1
(en)
*
|
2003-06-30 |
2005-02-03 |
Merck & Co., Inc. |
Radiolabeled cannabinoid-1 receptor modulators
|
US20050026983A1
(en)
*
|
2003-07-30 |
2005-02-03 |
Pfizer Inc |
Imidazole compounds and uses thereof
|
CA2551037A1
(en)
|
2003-09-22 |
2005-03-31 |
Banyu Pharmaceutical Co., Ltd. |
Novel piperidine derivative
|
JP4527729B2
(ja)
|
2003-12-08 |
2010-08-18 |
エフ.ホフマン−ラ ロシュ アーゲー |
新規チアゾール誘導体
|
TW200522944A
(en)
|
2003-12-23 |
2005-07-16 |
Lilly Co Eli |
CB1 modulator compounds
|
WO2005075450A2
(en)
|
2004-01-28 |
2005-08-18 |
F. Hoffmann-La Roche Ag |
Spiro-benzodioxoles and their use as cb1 antagonists
|
JP2007530690A
(ja)
|
2004-03-29 |
2007-11-01 |
メルク エンド カムパニー インコーポレーテッド |
11−β−ヒドロキシステロイドデヒドロゲナーゼ−1の阻害剤としてのジアリールトリアゾール
|
EP2305352A1
(en)
|
2004-04-02 |
2011-04-06 |
Merck Sharp & Dohme Corp. |
5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
|
BRPI0510679A
(pt)
|
2004-05-10 |
2007-12-26 |
Hoffmann La Roche |
compostos, processo para a sua manufatura, composições farmacêuticas que os contêm, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação dos receptores de cb1 e utilização desses compostos
|
ITMI20041033A1
(it)
*
|
2004-05-24 |
2004-08-24 |
Neuroscienze S C A R L |
Composti farmaceutici
|
ITMI20041032A1
(it)
|
2004-05-24 |
2004-08-24 |
Neuroscienze S C A R L |
Compositi farmaceutici
|
EP1781668A2
(en)
|
2004-07-12 |
2007-05-09 |
Cadila Healthcare Ltd. |
Tricyclic pyrazole derivatives as cannabinoid receptor modulators
|
US20060025448A1
(en)
|
2004-07-22 |
2006-02-02 |
Cadila Healthcare Limited |
Hair growth stimulators
|
JP2008509146A
(ja)
|
2004-08-06 |
2008-03-27 |
メルク エンド カムパニー インコーポレーテッド |
11−ベータ−ヒドロキシステロイドデヒドロゲナーゼ−1の阻害剤としてのスルホニル化合物
|
FR2874012B1
(fr)
|
2004-08-09 |
2008-08-22 |
Sanofi Synthelabo |
Derives de pyrrole, leur preparation et leur utlisation en therapeutique
|
WO2006020959A2
(en)
*
|
2004-08-13 |
2006-02-23 |
Amgen Inc. |
Substituted benzofused heterocycles
|
CA2581596A1
(en)
*
|
2004-09-29 |
2006-04-13 |
Schering Corporation |
Combinations of substituted azetidonones and cb1 antagonists
|
RU2394027C2
(ru)
|
2004-10-27 |
2010-07-10 |
Ф. Хоффманн-Ля Рош Аг |
Новые индольные или бензимидазольные производные
|
EP2127676A3
(en)
|
2004-11-01 |
2013-09-04 |
Amylin Pharmaceuticals, LLC |
Treatment of obesity and related disorders
|
US8394765B2
(en)
*
|
2004-11-01 |
2013-03-12 |
Amylin Pharmaceuticals Llc |
Methods of treating obesity with two different anti-obesity agents
|
EP1812418B1
(en)
|
2004-11-09 |
2010-10-27 |
F. Hoffmann-La Roche AG |
Dibenzosuberone derivatives
|
US20080319019A1
(en)
*
|
2004-12-23 |
2008-12-25 |
Leifeng Cheng |
Therapeutic Agents
|
WO2006067443A1
(en)
*
|
2004-12-23 |
2006-06-29 |
Astrazeneca Ab |
Therapeutic agents
|
AU2006203845A1
(en)
*
|
2005-01-10 |
2006-07-13 |
Alexandros Makriyannis |
Novel heteropyrrole analogs acting on cannabiniod receptors
|
US8853205B2
(en)
|
2005-01-10 |
2014-10-07 |
University Of Connecticut |
Heteropyrrole analogs acting on cannabinoid receptors
|
US20090286723A1
(en)
|
2005-02-11 |
2009-11-19 |
Amylin Pharmaceuticals, Inc. |
Hybrid Polypeptides with Selectable Properties
|
RU2404164C2
(ru)
*
|
2005-04-06 |
2010-11-20 |
Ф.Хоффманн-Ля Рош Аг |
Производные пиридин-3-карбоксамида в качестве обратных агонистов св1
|
US7737155B2
(en)
|
2005-05-17 |
2010-06-15 |
Schering Corporation |
Nitrogen-containing heterocyclic compounds and methods of use thereof
|
US20060278280A1
(en)
*
|
2005-05-23 |
2006-12-14 |
Tzai-Jen Yang |
Check valve
|
EP1890767A2
(en)
*
|
2005-05-27 |
2008-02-27 |
Pfizer Products Inc. |
Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
|
NZ562766A
(en)
|
2005-05-30 |
2011-03-31 |
Banyu Pharma Co Ltd |
Piperidine derivatives as histamine-H3 receptor antagonists
|
US7923465B2
(en)
*
|
2005-06-02 |
2011-04-12 |
Glenmark Pharmaceuticals S.A. |
Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
|
WO2006136502A1
(en)
*
|
2005-06-22 |
2006-12-28 |
F. Hoffmann-La Roche Ag |
( 6-FLU0R0-BENZ0[l, 3] DIOXOLYL) -MORPHOLIN-4-YL-METHANONES AND THEIR USE AS CBl LIGANDS
|
CA2518579A1
(en)
*
|
2005-08-05 |
2007-02-05 |
University Technologies International Inc. |
Method for appetite suppression
|
US20100216758A1
(en)
|
2005-08-10 |
2010-08-26 |
Makoto Ando |
Pyridone Compounds
|
BRPI0614649A2
(pt)
|
2005-08-11 |
2011-04-12 |
Amylin Pharmaceuticals Inc |
polipeptìdeos hìbridos com propriedades selecionáveis
|
EP1921065B1
(en)
|
2005-08-24 |
2010-10-20 |
Banyu Pharmaceutical Co., Ltd. |
Phenylpyridone derivative
|
EP1939194A4
(en)
|
2005-09-07 |
2010-12-08 |
Banyu Pharma Co Ltd |
AROMATIC SUBSTITUTED BICYLIC PYRIDONE DERIVATIVE
|
WO2007041052A2
(en)
|
2005-09-29 |
2007-04-12 |
Merck & Co., Inc. |
Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
|
JPWO2007049798A1
(ja)
|
2005-10-27 |
2009-04-30 |
萬有製薬株式会社 |
新規ベンゾオキサチイン誘導体
|
KR101318127B1
(ko)
|
2005-11-10 |
2013-10-16 |
엠에스디 가부시키가이샤 |
아자 치환된 스피로 유도체
|
EP1801098A1
(en)
|
2005-12-16 |
2007-06-27 |
Merck Sante |
2-Adamantylurea derivatives as selective 11B-HSD1 inhibitors
|
WO2007106721A2
(en)
*
|
2006-03-10 |
2007-09-20 |
Jenrin Discovery |
Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
|
US7629346B2
(en)
|
2006-06-19 |
2009-12-08 |
Hoffmann-La Roche Inc. |
Pyrazinecarboxamide derivatives as CB1 antagonists
|
US7781593B2
(en)
*
|
2006-09-14 |
2010-08-24 |
Hoffmann-La Roche Inc. |
5-phenyl-nicotinamide derivatives
|
WO2008039327A2
(en)
|
2006-09-22 |
2008-04-03 |
Merck & Co., Inc. |
Method of treatment using fatty acid synthesis inhibitors
|
EP2072519A4
(en)
|
2006-09-28 |
2009-10-21 |
Banyu Pharma Co Ltd |
DIARYLKETIMINDERIVAT
|
US20080108643A1
(en)
*
|
2006-11-03 |
2008-05-08 |
Forest Laboratories Holdings Limited |
Method for treating autism
|
CA2673359A1
(en)
|
2006-12-18 |
2008-06-26 |
7Tm Pharma A/S |
Cb1 receptor modulators
|
EP1935420A1
(en)
|
2006-12-21 |
2008-06-25 |
Merck Sante |
2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors
|
US8106086B2
(en)
|
2007-04-02 |
2012-01-31 |
Msd K.K. |
Indoledione derivative
|
PE20090142A1
(es)
*
|
2007-04-11 |
2009-02-19 |
Merck & Co Inc |
Derivados de furo[2,3-b] piridina sustituidos como moduladores del receptor canabinoide-1
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
AU2008261102B2
(en)
|
2007-06-04 |
2013-11-28 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
PT2176208E
(pt)
*
|
2007-07-30 |
2015-05-11 |
Zynerba Pharmaceuticals Inc |
Pró-fármacos de canabidiol, composições compreendendo pró- fármacos de canabidiol e métodos de utilização dos mesmos
|
US8133904B2
(en)
*
|
2007-09-07 |
2012-03-13 |
Jenrin Discovery, Inc. |
Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
|
KR20100098628A
(ko)
*
|
2007-11-14 |
2010-09-08 |
아밀린 파마슈티칼스, 인크. |
비만 및 비만 관련 질환 및 장애의 치료 방법
|
BRPI0822061A2
(pt)
*
|
2007-12-10 |
2015-06-23 |
7Tm Pharma As |
Moduladores do receptor canabinoide
|
WO2009099670A2
(en)
*
|
2008-02-08 |
2009-08-13 |
Nektar Therapeutics Al, Corporation |
Oligomer-cannabinoid conjugates
|
WO2009110510A1
(ja)
|
2008-03-06 |
2009-09-11 |
萬有製薬株式会社 |
アルキルアミノピリジン誘導体
|
US20090247619A1
(en)
*
|
2008-03-06 |
2009-10-01 |
University Of Kentucky |
Cannabinoid-Containing Compositions and Methods for Their Use
|
WO2009119726A1
(ja)
|
2008-03-28 |
2009-10-01 |
萬有製薬株式会社 |
メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体
|
EP2110374A1
(en)
|
2008-04-18 |
2009-10-21 |
Merck Sante |
Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
|
EP2810951B1
(en)
|
2008-06-04 |
2017-03-15 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
WO2009154132A1
(ja)
|
2008-06-19 |
2009-12-23 |
萬有製薬株式会社 |
スピロジアミン-ジアリールケトオキシム誘導体
|
ES2624828T3
(es)
|
2008-07-16 |
2017-07-17 |
Synergy Pharmaceuticals Inc. |
Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
|
US20110124674A1
(en)
|
2008-07-30 |
2011-05-26 |
Hiroyuki Kishino |
5/5-or 5/6-membered condensed ring cycloalkylamine derivative
|
IT1390848B1
(it)
|
2008-07-31 |
2011-10-19 |
Neuroscienze Pharmaness S C A R L |
Composti farmaceutici
|
EP2149370A1
(en)
*
|
2008-07-31 |
2010-02-03 |
Neuroscienze Pharmaness S.C. A R.L. |
Diazabicyclic compounds and microemulsions thereof
|
CA2741125A1
(en)
|
2008-10-22 |
2010-04-29 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
AU2009308980B2
(en)
|
2008-10-30 |
2013-02-28 |
Merck Sharp & Dohme Corp. |
Isonicotinamide orexin receptor antagonists
|
US8329914B2
(en)
|
2008-10-31 |
2012-12-11 |
Merck Sharp & Dohme Corp |
Cyclic benzimidazole derivatives useful as anti-diabetic agents
|
JP5514831B2
(ja)
|
2008-11-17 |
2014-06-04 |
メルク・シャープ・アンド・ドーム・コーポレーション |
糖尿病の治療のための置換二環式アミン
|
US20110243940A1
(en)
|
2008-12-16 |
2011-10-06 |
Schering Corporation |
Bicyclic pyranone derivatives and methods of use thereof
|
US20110245209A1
(en)
|
2008-12-16 |
2011-10-06 |
Schering Corporation |
Pyridopyrimidine derivatives and methods of use thereof
|
WO2010079241A1
(es)
|
2009-01-12 |
2010-07-15 |
Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion |
Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
|
US10053444B2
(en)
|
2009-02-19 |
2018-08-21 |
University Of Connecticut |
Cannabinergic nitrate esters and related analogs
|
IT1395724B1
(it)
|
2009-02-25 |
2012-10-19 |
Neuroscienze Pharmaness S C A R L |
Composti farmaceutici
|
IT1394400B1
(it)
*
|
2009-02-25 |
2012-06-15 |
Neuroscienze Pharmaness S C Ar L |
Composizioni farmaceutiche
|
IT1394860B1
(it)
|
2009-07-22 |
2012-07-20 |
Kemotech S R L |
Composti farmaceutici
|
CA2768577A1
(en)
|
2009-07-23 |
2011-01-27 |
Schering Corporation |
Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
|
WO2011011506A1
(en)
|
2009-07-23 |
2011-01-27 |
Schering Corporation |
Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
|
DE102009035649A1
(de)
*
|
2009-07-29 |
2011-02-03 |
Siemens Aktiengesellschaft |
Arzneistoff und Verfahren zur Erprobung eines Arzneistoffes
|
CA2779088A1
(en)
|
2009-11-16 |
2011-05-19 |
Mellitech |
[1,5]-diazocin derivatives
|
IT1396951B1
(it)
*
|
2009-12-18 |
2012-12-20 |
Neuroscienze Pharmaness S C A R L |
Composti farmaceutici
|
JP5540454B2
(ja)
|
2009-12-30 |
2014-07-02 |
シャンハイ フォチョン ファーマシューティカル カンパニー リミテッド |
ジペプチジルペプチダーゼ阻害剤
|
JP2013520502A
(ja)
|
2010-02-25 |
2013-06-06 |
メルク・シャープ・エンド・ドーム・コーポレイション |
有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
|
US8785634B2
(en)
|
2010-04-26 |
2014-07-22 |
Merck Sharp & Dohme Corp |
Spiropiperidine prolylcarboxypeptidase inhibitors
|
US9365539B2
(en)
|
2010-05-11 |
2016-06-14 |
Merck Sharp & Dohme Corp. |
Prolylcarboxypeptidase inhibitors
|
EP2579873A4
(en)
|
2010-06-11 |
2013-11-27 |
Merck Sharp & Dohme |
NOVEL PROLYLCARBOXYPEPTIDASE HEMMER
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
US8410107B2
(en)
|
2010-10-15 |
2013-04-02 |
Hoffmann-La Roche Inc. |
N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
|
US8669254B2
(en)
|
2010-12-15 |
2014-03-11 |
Hoffman-La Roche Inc. |
Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
|
CN105001219A
(zh)
|
2011-02-25 |
2015-10-28 |
默沙东公司 |
用作抗糖尿病药剂的新的环状氮杂苯并咪唑衍生物
|
JP5872591B2
(ja)
*
|
2011-09-30 |
2016-03-01 |
ナショナル ヘルス リサーチ インスティテュートス |
ピラゾール化合物
|
AR088352A1
(es)
|
2011-10-19 |
2014-05-28 |
Merck Sharp & Dohme |
Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
|
WO2014022528A1
(en)
|
2012-08-02 |
2014-02-06 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
JP2016516004A
(ja)
|
2013-02-22 |
2016-06-02 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
抗糖尿病二環式化合物
|
EP2970119B1
(en)
|
2013-03-14 |
2021-11-03 |
Merck Sharp & Dohme Corp. |
Novel indole derivatives useful as anti-diabetic agents
|
CA2905438A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
WO2014151200A2
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
EP2789619A1
(en)
|
2013-04-12 |
2014-10-15 |
Kemotech S.r.l. |
Pharmaceutical compounds wiht angiogenesis inbhibitory activity
|
KR102272746B1
(ko)
|
2013-06-05 |
2021-07-08 |
보슈 헬스 아일랜드 리미티드 |
구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
CA2949559C
(en)
|
2014-06-06 |
2023-08-29 |
Research Triangle Institute |
Apelin receptor (apj) agonists and uses thereof
|
ES2901114T3
(es)
|
2014-08-29 |
2022-03-21 |
Tes Pharma S R L |
Inhibidores de ácido alfa-amino-beta-carboximucónico semialdehído descarboxilasa
|
JP2019501899A
(ja)
|
2015-12-09 |
2019-01-24 |
リサーチ トライアングル インスティテュート |
改良アペリンレセプター(apj)アゴニストおよびその使用
|
AR109950A1
(es)
|
2016-10-14 |
2019-02-06 |
Tes Pharma S R L |
INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
|
US11072602B2
(en)
|
2016-12-06 |
2021-07-27 |
Merck Sharp & Dohme Corp. |
Antidiabetic heterocyclic compounds
|
CA3119509A1
(en)
|
2018-11-20 |
2020-05-28 |
Tes Pharma S.R.L |
Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxxylase
|
EP3924058A1
(en)
|
2019-02-13 |
2021-12-22 |
Merck Sharp & Dohme Corp. |
5-alkyl pyrrolidine orexin receptor agonists
|
US20230018413A1
(en)
|
2019-08-08 |
2023-01-19 |
Merck Sharp & Dohme Corp. |
Heteroaryl pyrrolidine and piperidine orexin receptor agonists
|
CA3125847A1
(en)
|
2020-07-27 |
2022-01-27 |
Makscientific, Llc |
Process for making biologically active compounds and intermediates thereof
|
JP7443625B2
(ja)
|
2020-08-18 |
2024-03-05 |
メルク・シャープ・アンド・ドーム・エルエルシー |
ビシクロヘプタンピロリジンオレキシン受容体アゴニスト
|